肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2022 西班牙专家共识：CAR-T治疗的管理和执行

2022-01-08 国外肿瘤科相关专家小组（统称） Clin Transl Oncol

CAR-TCAR-T治疗

CAR-T治疗细胞疗法代表了某些类型血液肿瘤患者预后和治疗方面的一场治疗革命。但其应用也存在一些新的挑战。本文主要针对CAR-T治疗的管理和执行提供共识指导。

中文标题：

2022 西班牙专家共识：CAR-T治疗的管理和执行

英文标题：

A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2022-01-08

简要介绍：

CAR-T治疗细胞疗法代表了某些类型血液肿瘤患者预后和治疗方面的一场治疗革命。但其应用也存在一些新的挑战。本文主要针对CAR-T治疗的管理和执行提供共识指导。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 西班牙专家共识：CAR-T治疗的管理和执行.pdf)] GetToolGuiderByIdResponse(projectId=1, id=337a01c002315172, title=2022 西班牙专家共识：CAR-T治疗的管理和执行, enTitle=A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper, guiderFrom=Clin Transl Oncol, authorId=0, author=, summary=CAR-T治疗细胞疗法代表了某些类型血液肿瘤患者预后和治疗方面的一场治疗革命。但其应用也存在一些新的挑战。本文主要针对CAR-T治疗的管理和执行提供共识指导。, cover=https://img.medsci.cn/2022110/1641818045988_1608702.png, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Sat Jan 08 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">CAR-T治疗细胞疗法代表了某些类型血液肿瘤患者预后和治疗方面的一场治疗革命。但其应用也存在一些新的挑战。本文主要针对CAR-T治疗的管理和执行提供共识指导。</span></p>, tagList=[TagDto(tagId=18370, tagName=CAR-T), TagDto(tagId=33720, tagName=CAR-T治疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=33720, guiderKeyword=CAR-T治疗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3731, appHits=47, showAppHits=0, pcHits=283, showPcHits=3683, likes=0, shares=12, comments=6, approvalStatus=1, publishedTime=Mon Jan 10 20:28:22 CST 2022, publishedTimeString=2022-01-08, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Mon Jan 10 20:35:05 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Thu Jan 04 06:23:35 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 西班牙专家共识：CAR-T治疗的管理和执行.pdf)])
2022 西班牙专家共识：CAR-T治疗的管理和执行.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1183421, encodeId=ab90118342123, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 12 07:25:49 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183071, encodeId=758111830e1c2, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 11 07:30:36 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183042, encodeId=5ed2118304208, content=期待有几分去学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:11:06 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182958, encodeId=9d5e1182958ae, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:19:09 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-01-12 微探

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1183421, encodeId=ab90118342123, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 12 07:25:49 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183071, encodeId=758111830e1c2, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 11 07:30:36 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183042, encodeId=5ed2118304208, content=期待有几分去学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:11:06 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182958, encodeId=9d5e1182958ae, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:19:09 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-01-11 微探

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1183421, encodeId=ab90118342123, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 12 07:25:49 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183071, encodeId=758111830e1c2, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 11 07:30:36 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183042, encodeId=5ed2118304208, content=期待有几分去学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:11:06 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182958, encodeId=9d5e1182958ae, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:19:09 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-01-11 lexi Liao

    期待有几分去学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1183421, encodeId=ab90118342123, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 12 07:25:49 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183071, encodeId=758111830e1c2, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 11 07:30:36 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183042, encodeId=5ed2118304208, content=期待有几分去学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211129/0708c577736746af9505e240c95bfe21/ed50f4e6812646388b702de78e18d26b.jpg, createdBy=e07e5430262, createdName=lexi Liao, createdTime=Tue Jan 11 03:11:06 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182958, encodeId=9d5e1182958ae, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:19:09 CST 2022, time=2022-01-10, status=1, ipAttribution=)]
    2022-01-10 ms4000001034418498

    学习学习

    0

相关指南

2021 EBMT/JACIE/EHA最佳实践建议：接受CAR-T细胞治疗的成人和儿童的管理

欧洲血液和骨髓移植学会(EBMT,European Society for Blood and Marrow Transplantation ) · 2021-12-16

嵌合抗原受体T细胞（CAR-T）产品申报上市临床风险管理计划技术指导原则（征求意见稿）

国家药品监督管理局药品审评中心（CDE） · 2021-09-18